equity raise unlikely due to the bridging loan before R&D tax benefit is received
the real concern and why I believe the selling from Gary and others has been so staunch is because of the news from GSK on their FDA approved myelofibrosis drug
PXS great but slow, Big Pharma appears to be working more in-house and only making big investments when significant positive data and analysis is produced by small biotechs for high commercial targets
PXS Price at posting:
3.6¢ Sentiment: None Disclosure: Held
